Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034363 | PMC |
| http://dx.doi.org/10.3389/fmedt.2023.1168278 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center's experience.
Front Oncol
December 2024
Clinic for Otorhinolaryngology, University Hospital Leipzig, Leipzig, Germany.
Introduction: The larynx organ preservation (LOP) trial DeLOS-II enrolled = 173 patients with advanced laryngeal/hypopharyngeal squamous cell carcinoma (LHSCC) amenable (only curatively resectable) through total laryngectomy (TL) to receive induction chemotherapy (IC) with TPF [docetaxel (T), cisplatin (P), and 5-fluorouracil (F)] (arm A, 85 patients) or additional cetuximab (E) weekly (arm B, 88 patients). Responders with endoscopic estimated tumor surface shrinkage (ETSS) ≥30% after 1 cycle IC (IC-1) received a further two cycles of IC followed by radiotherapy (RT), whereas TL was recommended for non-responders. Arm B failed to show superior 24-month laryngectomy-free survival (LFS) and overall survival (OS), the protocol-specified primary and secondary endpoints.
View Article and Find Full Text PDFNew insights into the management of homozygous familial hypercholesterolemia patients treated with lomitapide: a single-center experience.
Front Endocrinol (Lausanne)
January 2025
Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Naples, Italy.
Familial hypercholesterolemia (FH) is a genetic disease, usually with onset during childhood, characterized by elevated blood LDL cholesterol levels and potentially associated with severe cardiovascular complications. Concerning mutated genes in FH, such as , a small subset of FH patients presents a homozygous genotype, resulting in homozygous FH (HoFH) disease with a generally aggressive phenotype. Besides statins, ezetimibe and PCSK9 inhibitors, lomitapide (an anti-ApoB therapy) was also approved in 2012-2013 as an adjunctive treatment for HoFH.
View Article and Find Full Text PDFBackground: In humans, environmental enrichment (EE), as measured by the engagement in a variety of leisure activities, has been associated with larger hippocampal structure and better memory function. The present cross-sectional study assessed whether EE during early life (13-30 years) and midlife (30-65 years) is associated with better preserved memory-related brain activity patterns in older age.
Methods: In total, 372 cognitively unimpaired older adults (aged ≥60 years old) of the DZNE-Longitudinal Study on Cognitive Impairment and Dementia (DELCODE; DRKS00007966) were investigated.
This editorial explores the intricate landscape of supplement use in oncology, highlighting the growing interest and challenges surrounding their integration into cancer care. It discusses the disparity in regulatory oversight between supplements and pharmaceutical drugs, the blurred lines in their classification, and the ethical complexities in patient-doctor communication. The importance of transparency, shared decision-making, and realistic expectations is emphasized.
View Article and Find Full Text PDFOptimal use, combinations, and sequencing of therapies in advanced prostate cancer.
Expert Rev Clin Pharmacol
January 2025
Division of Oncology Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!